Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Two Reasons This Biotech Hardly Moved After a Successful Trial

Data doesn’t get much cleaner than this.

Adding Esperion Therapeutics‘  ECT-1002 to Pfizer Inc. (NYSE:PFE)‘s Lipitor lowered bad LDL cholesterol levels by 22%. Adding placebo to Lipitor didn’t change the LDL cholesterol levels at all. The difference between 22% and 0% reductions was statistically significant with a p-value of less than 0.0001. Or put another way, there’s a 0.01% chance the difference happened by chance alone.

Pfizer Inc. (NYSE:PFE)And yet Esperion is hardly up at all today. I think there are two reasons investors are being rightfully a little cautious.

Good but not great
ECT-1002 is certainly better than a dummy pill, but it’s not like there aren’t other options for patients to add onto Lipitor or another statin.

Merck & Co., Inc. (NYSE:MRK)‘s Zetia when added to a statin lowered LDL cholesterol by 25% in one of the clinical trials included on its label. The trials aren’t apples-to-apples comparisons, but it sure doesn’t look like ECT-1002 is that much better than Zetia.

And there’s a new class of drugs called PCSK9 slightly ahead of Esperion that have produced solid data when added to statins. Amgen, Inc. (NASDAQ:AMGN)‘s AMG-145 lowered LDL cholesterol levels by 43% to 55% depending on the dose. Pfizer Inc. (NYSE:PFE)’s RN-316 lowered LDL by 46% and 56% at two different doses.

I think PCSK9 drugs are likely better at lowering LDL cholesterol, but it’s hard to say by how much because patients in both trials started with cholesterol levels that were higher than the patients in the ECT-1002 trials.

The PCSK9 inhibitors have to be infused while ECT-1002 is more convenient because it’s taken orally, so even if the PCSK9 drugs are more potent, there’s likely a niche for ECT-1002 for patients that just need a little extra reduction in cholesterol to get to their goal.

Of course, producing 50% reductions and taken orally sure would be nice.

If you read far enough into the press release announcing the clinical trial results, you’ll find this sentence: “One patient had an elevated liver enzyme laboratory finding that resolved when ETC-1002 and [Lipitor] were discontinued.”

That’s a big red flag, Fools. Elevated liver enzymes are a sign of liver toxicity, one of the most frequent reasons that efficacious drugs are shelved.

On the conference call, management said the patient hadn’t taken statins before entering the trial, so it’s possible the Lipitor was the cause of the elevated liver enzymes.

We’ll know more as Esperion tests ECT-1002 on more patients — the data is certainly worthy of pushing forward — but I’d be very cautious until more safety data is available.

The article 2 Reasons This Biotech Hardly Moved After a Successful Trial originally appeared on and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!